Gametocyte Stiffening for Malaria Transmission Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies fail to effectively target and reduce the transmission of Plasmodium parasites, particularly Plasmodium falciparum, as they rely on mechanisms that do not adequately address the deformability of mature gametocytes, which are essential for parasite circulation and transmission.
Innovation Solution
Identifying and utilizing compounds such as TD-6450, NITD609, and L-THP, which increase the rigidity of infected red blood cells, making them less deformable and thus more susceptible to spleen clearance, thereby blocking malaria transmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current transmission-blocking strategies are used, then parasite transmission may be reduced to some extent, but they fail to effectively target mature gametocytes and their deformability mechanisms
Solution Approach 1:
The invention changes the physical parameter of gametocyte deformability by administering compounds that stiffen mature gametocytes, transforming them from a deformable state (enabling circulation and transmission) to a rigid state (enabling spleen clearance and blocking transmission). This parameter change directly addresses the failure of current strategies to target deformability mechanisms.
2Productivity
If mature gametocytes maintain their natural deformability, then they can circulate through the spleen and be transmitted by mosquitoes, but this enables parasite transmission
Solution Approach 1:
The invention converts the harmful property of gametocyte deformability (which enables transmission) into a beneficial property by using the same deformability mechanism as a target for intervention. By stiffening gametocytes, the invention transforms them from transmission-competent to transmission-blocking, while the spleen's natural clearance mechanism for rigid cells becomes the beneficial force eliminating the parasite.
3Reliability
If compounds that stiffen gametocytes are administered, then transmission is blocked by enhancing spleen clearance, but this requires identification of effective compounds with appropriate pharmacokinetics
Solution Approach 1:
The invention performs preliminary action by conducting in silico screening and in vitro validation to identify and characterize compounds with gametocyte-stiffening activity before clinical development. This preliminary work establishes proof of concept, identifies lead candidates (such as compounds from the artemisinin family), and validates the mechanism of action, thereby reducing the complexity of subsequent drug development and manufacturing efforts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified compounds effectively stiffen mature gametocytes, reducing their ability to circulate in peripheral blood and be transmitted by mosquitoes, providing a novel approach to block malaria transmission.
Implementation Method 1
Drug-induced stiffening of Plasmodium falciparum intra-erythrocytic sexual stages (mature gametocytes) is therefore expected to block the transmission of malaria
Implementation Method 2
The spleen clears rigid erythrocytes from the circulation
Data Source
AI summary
The spleen clears rigid erythrocytes from the circulation. Drug-induced stiffening of Plasmodium falciparum intra-erythrocytic sexual stages (mature gametocytes) is therefore expected to block the transmission of malaria By screening 13 555 compounds with spleen-mimetic microfilters, the inventors identified 82 compounds that stiffen mature gametocytes. Eight active families were identified, including known anti-malarial, antimicrobial or anticancer agents, amongst others. Hit prioritization based on accessible safety and pharmacokinetics data in humans identified 3 leading candidates. NITD609 displayed killing and stiffening effects (IC50 of 100 and 50 nM, respectively), while TD-6450 and L-THP had a pure or predominant stiffening effect (IC50 of 600 and 5 nM, respectively). These values are lower than or close to peak plasma concentrations in humans. Clinical trials with these strong malaria transmission-blocking candidates are envisioned.


